Recent research has demonstrated that the hypoglycemic drug dapagliflozin, a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor, reduces cardiac HBP and improves diastolic dysfunction in lipodystrophic T2DM mouse models (101). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.